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Evidence grades for the recommendations 
The following evidence grading has been used to determine the strength of the 
recommendations; the suggested audit standards; and the questions for areas that require 
future research.  
1A – Strong recommendation: high-quality evidence 
1B – Strong recommendation: moderate-quality evidence 
1C – Strong recommendation: low-quality evidence 
1D – Strong recommendation: very low-quality evidence 
2A – Weak recommendation: high-quality evidence 
2B – Weak recommendation: moderate-quality evidence 
2C – Weak recommendation: low-quality evidence 
2D – Weak recommendation: very low-quality evidence 
 
Search strategy 
The recommendations are based on a systematic review of the Cochrane Library, 
PubMed/MEDLINE, Google Scholar and Embase, using the following key words: type 1 
diabetes, insulin, chronic kidney disease, nephropathy, hypoglycaemia, insulin, 
sulfonylureas, metformin, SGLT-2 inhibitors, pioglitazone, DPP-4 inhibitors, GLP-1 analogues 
and meglitinides. 
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1 Introduction: glycaemic targets in the 
prevention and management of diabetic 
nephropathy and chronic kidney disease 
The management of diabetes is predicated on the basis of reducing hyperglycaemia to 
improve hyperglycaemic symptoms, with supportive evidence that this will prevent the 
onset, and slow down progression, of renal and vascular complications over time.  
The precise level of glycaemic control that delivers benefit remains contentious because, 
inevitably, the individualised approach to care and the evidence base from different cohorts 
do not allow clear extrapolation. The glycaemic management of type 1 diabetes and type 2 
diabetes and the respective renal benefits require separate consideration, which in part 
reflects the different evidence base and lifetime risks of complications, and the greater risk 
for hypoglycaemia that arises when several concurrent therapies are used alongside insulin 
as renal function deteriorates.  
In addition, the risk–benefit equation of tighter glycaemic control for renal and vascular 
complications alters as nephropathy / chronic kidney disease (CKD) progresses. 
Recent national clinical guidelines have not distinguished between glycaemic targets for 
those with or without diabetic nephropathy (DN)-CKD,1,2 and consensus groups have 
extrapolated from contemporary general recommendations, such as with Kidney Disease 
Outcomes Quality Initiative (KDOQI) in 2012, which suggested a target HbA1c level of 7% 
(53 mmol/mol) in those with CKD.3  
By contrast, the more recent European Renal Best Practice (ERBP) guidance in 2015 
recognised the lack of prospective randomised trials in CKD stage 3b or worse, and 
suggested ‘vigilant attempts to tighten glycaemic control when [HbA1c] values were >8.5% 
(69 mmol/mol)’ but recommended against tighter glycaemic control, given the 
hypoglycaemia risk.4  
A retrospective observational case cohort study found that HbA1c levels of <6.5% 
(48 mmol/mol) and >8% (63 mmol/mol) were associated with increased mortality in patients 
with CKD stages 3–4.5 
The most recent Cochrane collaborative meta-analysis from 2017 found that there were 
comparable risks of renal failure, death and major cardiovascular events among patients 
with stringent glycaemic control (HbA1c <7% (54 mmol/mol)), as opposed to those with less 
tight control, beyond small clinical benefits on the onset and progression of 
microalbuminuria.6  
Type 1 diabetes    
The Diabetes Control and Complications Trial / Epidemiology of Diabetes Interventions and 
Complications (DCCT/EDIC) studied adolescents and adults with type 1 diabetes who were 
intensively managed for a mean duration of 6.5 years to a target HbA1c of 6% 
(43 mmol/mol) (achieved 7.2% (55 mmol/mol)). The study clearly demonstrated a reduced 
incidence for the development and progression of microalbuminuria and macroalbuminuria 
in the primary and secondary prevention groups.7 Furthermore, ongoing surveillance for up 
to 18 years with less intensive glycaemic control (HbA1c subsequently maintained at a mean 
of 8% (63 mmol/mol)) revealed a legacy effect. That is, the intensive group continued to 
experience lower rates of incident microalbuminuria and macroalbuminuria but also had less 
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progression to CKD (estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2 ) and 
hypertension. At follow-up, however, the intensive group’s glycaemic control was 
indistinguishable from the control group.8 
At trial entry, none of the subjects in DCCT had CKD (the GFR estimated from creatinine 
clearance (CrCl) averaged 128 mL/min in both the primary and secondary prevention 
groups). Urinary albumin excretion was normal in the primary prevention group and was 
<140 µg/minute (mean 14 µg/minute) in the secondary prevention group.7 
A recent country-wide, registry-based observational study from Sweden confirmed the 
recognised excess mortality from type 1 diabetes compared with the general population, 
even with mean updated HbA1c values of <52 mmol/mol. Increased HbA1c values remained 
a powerful risk factor for death after adjustment for renal complications, which indicates a 
residual risk associated with poor glycaemic control.  
All-cause and cardiovascular mortality, however, in those with renal disease was virtually 
unchanged for patients with a time-updated HbA1c of 53–62 mmol/mol versus those with 
values of 52 mmol/mol or lower, which suggests that there is no additional benefit of tighter 
glycaemic control in those with type 1 diabetes who have renal disease.9 Thus it would be 
appropriate to reduce the development and progression of nephropathy via tight glycaemic 
control in younger patients (HbA1c target individualised to 48–58 mmol/mol), with a 
requirement to at least maintain moderate control (HbA1c of <63 mmol/mol) after a period 
of 10 years. There are, however, vascular benefits from tight glycaemic control (target 
HbA1c of 48–58 mmol/mol) over a longer period in younger patients with type 1 diabetes.  
The current UK National Institute for Health and Care Excellence (NICE) guidance to aim for 
the even tighter target HbA1c of 48 mmol/mol utilises the DCCT target10 which, although 
rarely achieved in that study, reduced both the progression of microalbuminuria and 
normoalbuminuric progression to microalbuminuria. From intervention studies with type 1 
diabetes patients who have DN-CKD, there is no current evidence that renal or other 
outcomes are improved by achieving an HbA1c of 48 mmol/mol.  
While recognising that individualised care targets should apply, it may still be broadly 
reasonable to aim for an HbA1c of 58–62 mmol/mol in type 1 diabetes patients who have 
DN-CKD and/or CKD stages 3–4, unless values of 48–58 mmol/mol are achievable in younger 
patients (below the age of 40 years) who are on an intensive self-management regime with 
documented hypoglycaemia avoidance and an intensive insulin regime on continuous 
subcutaneous insulin infusion (CSII) or multiple doses of insulin therapy.  
The Joint British Diabetes Societies (JBDS) guidelines for patients with diabetes of any sort 
who are on haemodialysis recommended HbA1c targets of 58–68 mmol/mol. This was based 
on U-shaped survival curves at values above and below this range and the inherent 
challenge of assessing glycaemic control in the context of related renal anaemia,11 which is 
present in 18–27% of patients with CKD stage 3 and is even more prevalent in those with 
more advanced CKD.12,13 The basis for renal anaemia can affect the level of HbA1c, with the 
normochromic secondary anaemia leading to falsely lower HbA1c14 while iron deficiency 
artefactually elevates the HbA1c value.15  
Type 2 diabetes  
With the exception of younger patients who have type 2 diabetes (below the age of 40) 
where the lifetime renal–cardiovascular disease risk may justify similar glycaemic targets to 
those for patients with type 1 diabetes, the evidence base for intensive glycaemic control 
comes from several sources with broadly different trial design and outcomes.  
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The Steno-2 randomised trial was conducted in 80 patients with microalbuminuria, and 
reported at intervals over 21 years’ follow-up, following a mean of 7.8 years of intensified 
glycaemic control as part of a package of multiple cardiovascular disease risk factor 
interventions and lifestyle modification. Although the target HbA1c was set at 48 mmol/mol, 
the mean HbA1C that was achieved in the study with an insulin-dominant regime was 
63 mmol/mol. At various time points there was clear evidence that a reduced number of 
complications were evolving and developing, including cardiovascular and microvascular 
(including albuminuric) outcomes.16,17 
With respect to renal outcomes, in the Steno-2 randomised trial there was a 48% significant 
risk reduction in the progression to macroalbuminuria through multiple risk factor 
intervention. Although the sample size was small, there was also a borderline significant 
reduction in progression to end-stage renal disease (ESRD) (p=0.06).  
One key message of the multiple risk factor approach was that, in keeping with other studies 
that demonstrated a legacy effect of early control, the continued benefits were apparent 
after a further 13-year follow-up, despite there being comparative HbA1c levels of 
58 mmol/l and 59 mmol/l in the intensive and control groups at 21 years’ follow-up.17 
By contrast, the ACCORD study design (with a target HbA1c of 42 mmol/mol and a broadly 
based intensive insulin regime) found that, at the stage of CKD, intensive glycaemic control 
led to increased cardiovascular risk and no benefit in terms of the progression of renal 
disease.18  
In patients who did not have CKD at trial entry, there was a delay in the onset of albuminuria 
but no reduction in their progress towards renal failure or the need for renal replacement 
therapy, and this was achieved at the cost of a high risk for severe hypoglycaemia and 
increased mortality.19 
The ADVANCE study was a predominantly sulfonylurea-based study and it recorded that 
intensive glucose control to a target HbA1c of 6.5% (48 mmol/mol) reduced the 
development and progression of both albuminuric and glomerular filtration outcomes in 
patients with type 2 diabetes, although the number of events was low.20 Over 5 years, the 
numbers needed to treat (NNT) to prevent one end-stage renal event ranged from 410 
participants in the overall study to 41 participants with macroalbuminuria at baseline.21,22 
The longer-term, 6-year follow-up of the ADVANCE study found that, while blood pressure 
(BP) control delivered persistent albeit attenuated benefits in terms of mortality, there was 
no evidence that glycaemic control led to macrovascular or mortality benefits in the longer 
term.21,22  
Two recent meta-analyses demonstrated that, although intensive glucose control (target 
HbA1c 6.1–7.1% (43–54 mmol/mol)) can lead to a reduced incidence of the surrogate renal 
measures of microalbuminuria and macroalbuminuria in patients with type 2 diabetes, there 
was no significant impact on clinical renal outcomes such as a doubling of serum creatinine, 
progression to ESRD, death from renal disease or other complications.23,24 A more recent 
meta-analysis included data from the Veteran Affairs (VA) and UK Prospective Diabetes 
Study (UKPDS) studies to imply that intensive glycaemic control had benefits in reducing 
these hard renal outcomes, but the heterogeneity of glycaemic targets limits the validity of 
that conclusion.25  
Given these discrepancies, the Cochrane collaboration has recently initiated a review to 
examine the efficacy and safety of insulin and other pharmacological interventions for 
lowering blood glucose in patients with diabetes and CKD.26 
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The JBDS has already reported and suggested an HbA1c of 58–68 mmol/mol in patients with 
diabetes who are on haemodialysis, given the hypoglycaemic and cardiovascular safety 
considerations and the inherent inaccuracy of HbA1c, with falsely lower values in those with 
anaemia in the context of CKD.11 
On balance, whereas the lifelong risk that hyperglycaemia will lead to the development and 
progression of DN-CKD (and other complications) requires a more intensive glycaemic-
lowering strategy in those with early onset type 2 diabetes diagnosed before the age of 40, 
options for intensive glycaemic control after that point with an insulin-intensive regime do 
not appear to be appropriate with HbA1c levels of <7% (53 mmol/mol). 
The recent cardiovascular safety studies with non-insulin based therapies among cohorts of 
patients with established cardiovascular disease using empagliflozin and the daily and 
weekly glucagon-like peptide-1 (GLP-1) analogues included a cohort with established DN-
CKD, and found that these patients had less evolution of albuminuria to evident proteinuria 
with an attained HbA1c of 7.3–7.6% (56–60 mmol/mol).  
In the Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients 
(EMPA-REG) study group , with the sodium glucose co-transporter-2 (SGLT-2) inhibitor 
empagliflozin, virtually all had established cardiovascular disease at baseline and all had an 
eGFR of >30 mL/min/1.73 m2. CKD stage 3a was present in 17.8% of participants and 7.7% of 
participants had CKD stage 3b. In addition, 28.7% had microalbuminuria and 11% had 
macroalbuminuria.27 The cohort with a reduced eGFR had a baseline HbA1c of 8.1% 
(65 mmol/mol), which fell to 7.6% (60 mmol/mol) – only 0.3% (3 mmol/mol) lower than the 
placebo. Thus despite there being only modest differences in glycaemic control that was not 
intensified, incident or worsening nephropathy (progression to macroalbuminuria) was 
reduced by 39%, with a 44% risk reduction in doubling of serum creatinine. Although there 
were only small numbers, a 55% relative risk reduction in the need for renal replacement 
therapy was also seen.27 A more recent evaluation of albuminuria progression confirmed 
these findings.28  
In the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome 
Results (LEADER) study, the majority of participants (72.4%) had cardiovascular disease at 
entry and 24.7% had CKD. The mean HbA1c of 8.7% (72 mmol/mol) at entry was set against 
a target HbA1c of 7% (53 mmol/mol), and the achieved HbA1c with liraglutide of 7.6% (60 
mmol/mol) was only 0.4% (4 mmol/mol) lower than in the control group. There was a 22% 
reduction in the incidence of nephropathy, but solely on the basis of proteinuria reduction, 
with no impact on more advanced renal measures.29  
In the Trial to Evaluate Cardiovascular and Other Long-term Outcomes with Semaglutide in 
Subjects with Type 2 Diabetes (SUSTAIN -6) with the weekly GLP-1 analogue semaglutide, 
the most effective glycaemic treatment was achieved using local best practice. Established 
cardiovascular disease was highly prevalent (83%) and 23.4% of participants had evident 
CKD at trial entry. From an HbA1c at baseline of 8.7% (72 mmol/mol), the active treatment 
led to a reduction in HbA1c to 7.3–7.6% (56–60 mmol/mol) depending on the dosage, which 
was 0.7–1% (7–10 mmol/mol) lower than the control group. New or worsening nephropathy 
was reduced by 36% with active treatment, essentially through a reduction in progression to 
macroalbuminuria.30 
In these studies, the control group had modestly poorer glycaemic control without these 
beneficial renal outcomes, which suggests that renoprotective non-glycaemic-based 
mechanisms may explain the observations.  
The following sections focus in more detail on the available glucose-lowering therapies for 
patients who have diabetes and DN-CKD.  
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At present, it would be prudent to consider an HbA1c target of 58 mmol/mol for most 
patients with type 2 diabetes and DN-CKD if they are on an insulin-dominant regime, and a 
target of up to 68 mmol/mol in older patients with more advanced CKD, especially where 
they have renal anaemia.  
It remains to be seen whether it is appropriate and safe to have a lower glycaemic HbA1c 
target of 52 mmol/mol in patients who are treated with less insulin and more GLP-1- and 
SGLT-2 inhibitor-focused treatments when the eGFR is >30 mL/min/1.73 m2, both when a 
patient does and does not have cardiovascular disease.  
From the current evidence, there is no basis to seek HbA1c values of lower than 
52 mmol/mol in older patients with type 2 diabetes and DN-CKD. 
Conclusion  
Individualised HbA1c targets should be applied in the management of patients with diabetes 
and DN-CKD, using the levels suggested in Table 1. It is, however, important to ensure that 
anaemia has been excluded or considered when using HbA1c to assess glycaemia. In 
addition, given the potential for the deterioration of renal function over time, at least annual 
monitoring of GFR is necessary, as this could impact on the type and dosage of diabetes 
therapies, as well as the appropriate glycaemic target. The selection of individual classes of 
agent, tailored to the additional comorbidities that are frequently seen alongside DN-CKD, 
will also influence therapy selection (Table 2). In addition, certain combinations of different 
classes of agents would need judicious consideration (Table 3). Although these current 
guidelines focus on the individual classes of glucose-lowering agent, combinations of 
different classes will frequently be used to manage diabetes in patients with CKD. There is a 
relative dearth of studies that specifically evaluate different drug combinations in patients 
with kidney disease, and this is clearly an area for both further research and current clinical 
audit (Table 4).  
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Table 1 Glycaemic targets in patients with diabetes and DN-CKD 
 Glycaemic target Note 
Type 1 
diabetes  
48–58 mmol/mol (6.5–7.5%)  Younger patients within 10 years’ 
duration of diabetes and variable 
microalbuminuria–CKD stage 2 
58–62 mmol/mol (7.5–7.8%)  The majority of patients with 
proteinuria and/or CKD stages 3–
4 
58–68 mmol/mol (7.5–8.5%)  Patients with CKD stage 5-dialysis 
Type 2 
diabetes 
48–58 mmol/mol (6.5–7.5%)  For the majority of patients who 
are aged <40 years, or have CKD 
stages 1–2 (no basis to aim for 
<52 mmol/mol (6.9%) unless the 
patient is aged <40 years and has 
CKD stages 1–2) 
52–58 mmol/mol (6.9–7.5%)  For those with CKD stages 3–4 
this target may be appropriate 
with a GLP-1–SGLT-2 inhibitor-
based treatment regime without 
insulin 
58–68 mmol/mol (7.5–8.5 %)   For those with CKD stages 3–4-
proteinuria who are on an insulin-
based regime, and those with 
CKD stage 5 who are on dialysis 
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Table 2 Non-renal and glycaemic contraindications to the selection of blood glucose 
lowering therapies in patients with DN-CKD 
Condition Drug Note 
Retinopathy  Pioglitazone Absolute contraindication in diabetic maculopathy 
Semaglutide  Relative contraindication in moderately hyperglycaemic 
patients (HbA1c >8.5% (68 mmol/mol)) who have moderate 
to severe diabetic retinopathy: caution is advised  
Bone health Pioglitazone Absolute contraindication in patients who have had previous 
osteoporotic fractures; or relative contraindication in those 
with post-menopausal osteoporosis with neuropathy 
SGLT-2 
inhibitors 
Relative contraindication of canagliflozin in patients with 
established osteoporotic fractures; no other current SGLT-2 
inhibitor bone health limitations are identified 
Feet health SGLT-2 
inhibitors 
Absolute contraindication of canagliflozin if a patient has 
had previous forefoot amputation and/or active diabetic 
foot disease; relative contraindication of other SGLT-2 
inhibitors in similar circumstances: no risk with empagliflozin 
is identified  
Cardiac failure Pioglitazone  Absolute contraindication in patients with established 
treated heart failure and where at-risk patients have a raised 
serum brain natriuretic peptide (BNP)  
Saxagliptin  Absolute contraindication in patients with treated 
established heart failure 
Pancreatic 
health 
GLP-1 analogues Absolute contraindication of GLP-1 analogues where a 
patient has previously documented pancreatitis; relative 
contraindication in patients who are at risk of pancreatitis 
with raised triglycerides, those on steroid therapy, those 
using other agents that are associated with pancreatitis or 
those with documented alcoholism 
Bladder 
health 
SGLT-2 
inhibitors 
Pioglitazone 
Relative contraindication of all medications in this class in 
patients who have documented neuropathic bladder and 
recurrent urinary infections 
Bladder cancer – no current absolute contraindication to 
continuation of pioglitazone and SGLT-2 inhibitors; relative 
contraindication/caution to initiation of pioglitazone and 
SGLT-2 inhibitors in those with bladder cancer or without 
investigation of unexplained haematuria 
Biliary tract 
health 
Liraglutide Relative contraindication if a patient has active gall bladder 
disease 
 
Table 3 Cautions when using combinations of drug classes to treat diabetes in patients who have CKD  
1 Insulin and sulfonylurea combination in patients with more advanced CKD (stages 4–5) 
2 SGLT-2 inhibitors and pioglitazone combination in patients with evident metabolic bone 
disease  
3 Insulin and pioglitazone combination in patients with documented fluid retention and/or a 
high risk of (or established) cardiac failure  
4 The lack of clinical benefit with the combination of DPP-4 inhibitor and GLP-1 analogue 
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Traditionally, the licensing of medicinal products in relation to renal dysfunction utilised CrCl 
to define cut-off points. With the advent of equation related estimated GFR (eGFR), we 
would no longer recommend measuring CrCl, which is less reliable in the clinic environment. 
We would recommend that eGFR is utilised, preferably using the more accurate Chronic 
Kidney Disease Epidemiology Collaboration (CKD-EPI) equation when determining whether 
certain therapies they can be used or for adjusting medication dosages in diabetes.31 
It is important to recognise that eGFR equations that are currently in use underestimate 
kidney function in obese patients (BMI >30 kg/m2) with type 2 diabetes.32 In these 
circumstances, the Cockcroft–Gault equation could be used 
(www.kidney.org/professionals/KDOQI/gfr_calculatorCoc) as long as there is appropriate 
sick day guidance in effect and that the kidney function is monitored appropriately to ensure 
that the treatment is stopped when the renal function moves out of the licensing range. 
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Table 4 Practical advice for healthcare workers who are managing patients with type 2 diabetes and CKD (eGFR level) and action to be taken 
eGFR level Medication and action to be taken 
Pioglitazone Metformin Nateglinide and repaglinide 
For all patients 
 
 Exclude a past medical history of bladder 
cancer or uninvestigated haematuria, heart 
failure or significant fluid retention. 
 Practitioners should weigh up the glycaemic 
benefit of pioglitazone against the risk of bone 
fractures. 
 Consider discontinuing pioglitazone in patients 
who develop osteoporotic fractures. 
 Practitioners have to weigh up the glycaemic and 
cardiovascular benefits against the rare risk of 
associated lactic acidosis. 
 Practitioners should provide all patients with the 
information leaflet Advice for patients taking 
metformin. 
 Practitioners have to weigh up the risk of 
hypoglycaemia. 
>60 mL/min/1.73 m2  No renal contraindication to pioglitazone.  No renal contraindication to metformin.  
 Some of these patients are at increased risk due to 
other risk factors (see advice for increased vigilance 
groups in the bottom row of this table). 
 Continue or commence nateglinide or repaglinide. 
 Advise patients to monitor their capillary blood 
glucose (CBG) 2 hours after taking the medication 
and to take precautions when driving. 
45–60 mL/min/1.73 m2  Continue use of pioglitazone in patients who 
are established on the agent but monitor for 
fluid retention 3–6/12ly thereafter. 
 For new patients who have no major fluid 
retention, pioglitazone can be started at 15 
mg once daily, and titrated up, based on the 
effectiveness and development of fluid 
retention in 2/52ly. 
 Continue use in patients who were established on the 
agent, but review the dose in light of glucose control 
needs. 
 For new patients who have no major active 
comorbidities, metformin commencement can be 
considered if age-related life expectancy is normal 
and vascular/diabetes risks are present. 
 Increase monitoring of renal function (to every 3–6 
months). 
30–45 mL/min/1.73 m2  In patients who are established on 
pioglitazone, monitor for fluid retention every 
3–6/12ly. 
 Patients can be started at 15 mg once daily 
and titrated up, based on the effectiveness 
and development of fluid retention in 2/52ly. 
 Continue or commence metformin with caution and 
explain the risks and benefits to the patient. 
 Use the lowest dose that achieves glycaemic control 
(suggest a 50% dose up to 1,000 mg/day). 
 Closely monitor renal function (every 3 months). 
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<30 mL/min/1.73 m2   In patients who are established on 
pioglitazone, monitor for fluid retention 
3/12ly.  
 Patients can be started at 15 mg once daily 
and titrated up, based on the effectiveness 
and development of fluid retention in 2/52ly. 
 At this level of renal function we cannot give firm 
recommendations about the ongoing use of 
metformin.  
 Some specialists may choose to use the agent in 
selected patients where they see that the benefits 
outweigh the risks. 
 Pharmacokinetic work would suggest that if 
metformin is used, a dose of 500–1,000 mg/day 
would result in 95% of people having peak metformin 
concentrations of <5 mg/L. 
 Consider measuring the true GFR directly, especially in 
patients who are obese. The Cockcroft–Gault formula 
may give a better reflection of eGFR in obese patients, 
and may allow the safe use of metformin in patients 
who have a low GFR.   
 Review the dose of nateglinide or repaglinide if 
the patient is already taking it, and consider a 
reduction based on their CBG.  
 Advise patients to monitor their CBG 2 hours after 
taking medication and to take precautions when 
driving.  
 Commence nateglinide or repaglinide at half the 
regular dose. 
Dialysis  Patients can be started at 15 mg once daily 
and titrated up, based on the effectiveness 
and development of fluid retention in 2/52ly 
(note the risk of fluid retention is offset by 
dialysis).  
 In patients who are established on 
pioglitazone, monitor for fluid retention 
3/12ly. 
  Not licensed, but not contraindicated, so it can be 
considered. 
 Continue or commence repaglinide at half the 
regular dose. 
 Advise patients to take precautions when driving.  
 Increased monitoring is required while a patient is 
on these agents. 
AKI (or at risk of AKI)  Review and consider (temporarily) stopping* metformin 
in patients who: 
 have acute changes in renal function (a fall in eGFR of 
>10 mL/min/1.73 m2 over a period of days or weeks) 
 are at risk of AKI such as: 
o acute volume depletion and dehydration eg 
gastrointestinal upset, stomas, change in 
diuretic dose 
o during operative procedures with a high risk of 
hypotension or volume depletion 
o in the presence of hypotension or shock, eg 
severe infection 
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o intravascular administration of iodinated 
contrast agents (stop metformin on the day of 
and 2 days after X-ray related intravenous 
contrast use) 
o co-administration with nephrotoxic drugs, eg 
non-steroidal anti-inflammatory drugs 
(NSAIDs)  
o patients with acute illness who are also on 
drugs that are known precipitants of AKI in 
association with any angiotensin-converting 
enzyme (ACE) inhibitors or angiotensin 
receptor blockers (ARBs) (such as non-
steroidal anti-inflammatory drugs (NSAIDs)), 
especially combined with diuretics 
 those with previous episodes of AKI. 
*Duration of stopping metformin should be based on the 
likely period of risk. In general it should be resumed at a low 
dose after discharge. 
Recovery from AKI   Once urine flow has returned to normal and GFR is 
>30 mL/min/1.73 m2, resume metformin at a low 
dose (eg 500–1,000 mg/day). 
 Monitor glucose control in outpatients and primary 
care before considering the further need for 
increasing doses. 
 
Increased vigilance  Increased vigilance is needed for the following groups of 
patients who are likely to be at a higher risks of lactic 
acidosis even with normal renal function:   
 those with decompensated cardiac or respiratory 
failure 
 those with acute conditions that may cause tissue 
hypoxia, eg recent myocardial infarction (MI) or 
shock 
 those with hepatic insufficiency, acute alcohol 
intoxication or alcoholism. 
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2 Insulin therapy  
Recommendations 
1 There is no firm evidence that insulin therapy reduces the risk of progressive renal 
disease. Therefore the aim of insulin therapy should be to improve glycaemic control 
and improve quality of life, with a low risk of hypoglycaemia (Grade 1C). 
 
2 Insulin requirements are likely to rise in the early stages of diabetic nephropathy (DN) 
due to increased insulin resistance (Grade 1C). 
 
3 As glomerular filtration rate (GFR) declines, insulin requirements are likely to diminish 
through reduced renal insulin clearance, and doses should be reduced as GFR declines, 
especially in chronic kidney disease (CKD) stage 3b and below. In patients with CKD stage 
3b and below who are on insulin, and whose HbA1c is 58 mmol/mol or below, a 
reduction of insulin doses should be considered (Grade 1C).  
 
4 Patients with diabetes and CKD who are treated with insulin should undertake regular 
glucose monitoring and be encouraged to manage their own diabetes as far as possible 
(Grade 1C). 
 
5 In patients who are less likely to be able to comply with the requirements of a basal 
bolus regime, once daily regimes with longer-acting insulins should be considered 
(Grade 1D). 
 
6 If patients have troublesome hypoglycaemia on neutral protamine Hagedorn (NPH) 
insulin, conversion to analogue insulins may be of benefit (Grade 1C). 
 
7 There is no evidence of benefit from biphasic premixed insulin administered once, twice 
or three times daily in patients with CKD stages 3–5. This regimen, however, may be 
useful in individual patients who have poorly controlled diabetes on a once daily insulin 
regimen (Grade 2C). 
 
8 Care should be taken when combining insulin with a sulfonylurea in patients with CKD 
stages 3–5, due to the high risk of hypoglycaemia (Grade 1B). 
Areas that require further research 
1 Does insulin therapy reduce the risk of progressive renal disease in patients with DN? 
 
2 Is there a role for 50:50 mixed insulins in patients with DN and progressive renal 
disease? 
 
3 Is there a role for continuous subcutaneous insulin infusion (CSII) in patients with DN 
and progressive renal disease? 
 
4 Is there a role for biosimilars or insulin−GLP-1 analogue mixtures in patients with CKD? 
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5 What is the efficacy and safety of different insulin regimes in combination with a 
sulfonylurea at different stages of CKD? 
Audit standards 
1 The proportion of patients with CKD stage 3b and below who are on insulin and whose 
HbA1c is 58 mmol/mol or below, whose insulin dose has been reduced.  
 
2 The proportion of insulin-treated patients with CKD stage 3b and below who are 
assessed for frequency and awareness of hypoglycaemia and have recorded severe 
acute hypoglycaemia episodes that required ambulance assistance.  
 
3 The proportion of patients who have an eGFR of <60 mL/min/1.73 m2 (or 
<45 mL/min/1.73 m2 on insulin therapy) in combination with sulfonylureas, and HbA1c 
values below 53 mmol/mol. 
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3 Sulfonylureas  
Recommendations  
1 Patients with type 2 diabetes and chronic kidney disease (CKD) who are on sulfonylurea 
(SU) treatment are at increased risk of hypoglycaemia. We therefore advise regular 
capillary blood glucose (CBG) monitoring in this patient group. For patients who have an 
estimated glomerular filtration rate (eGFR) of <45 mL/min/1.73 m2, CBG monitoring 
should be mandatory (Grade 2B). 
2 Gliclazide and glipizide are metabolised in the liver and are therefore the preferred SUs 
for patients with type 2 diabetes and CKD. Given the absence of excess cardiovascular 
events in a randomised trial, gliclazide should be the preferred choice of drug (Grade 
1B).  
3 We suggest that a sub-maximal dosage of gliclazide and glipizide is used in patients with 
an eGFR of <45 mL/min/1.73 m2 (Grade 2B). 
4 We suggest that SUs should be avoided alongside insulin in patients with an eGFR of 
<45 mL/min/1.73 m2, unless there is clear evidence of the absence of hypoglycaemia 
(Grade 2B/C).  
5 We suggest that gliclazide and glipizide should be avoided when a patient’s eGFR is 
<30 mL/min/1.73 m2, as this therapy is off licence in this scenario (Grade 2B). 
6 The safety profiles and pharmacokinetics of glibenclamide, glimepiride and tolbutamide 
do not support their use in patients with CKD, and we suggest that they should be 
avoided in such patients (Grade 2B). 
Areas that require further research 
1 What is the relationship between SUs and hypoglycaemia (with or without concomitant 
insulin therapy) in patients with CKD? 
2 What is the SU-related mortality in patients with CKD?   
3 A head-to-head comparison of the efficacy and hypoglycaemic risk between 
gliclazide/glimepiride and insulin or in combination. 
Audit standards 
1 The proportion of patients with CKD who are on SUs and who regularly monitor their 
CBG.  
2 The proportion of patients with an eGFR of <30 mL/min/1.73 m2 who are on SUs and 
who regularly monitor their CBG. 
3 The proportion of patients who are on individual SUs, according to CKD stage and 
frequency of severe acute hypoglycaemic episodes (SAHE), who have recorded 
ambulance call outs and hospital admissions.  
4 The proportion of patients with an eGFR of <60 (and <45) mL/min/1.73 m2 who are on 
SUs, and the dosage used. 
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5 The proportion of patients with an eGFR of <60 (and <45) mL/min/1.73 m2 who are on 
SUs in combination with insulin therapy who have an HbA1C of 53 mmol/mol (<6.5%). 
6 The documented sick day guidance that is provided to patients with CKD who are on SUs 
and other agents. 
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4 Meglitinides 
Recommendations 
1 Meglitinides can be considered for use in patients with type 2 diabetes and chronic 
kidney disease (CKD) as a monotherapy (repaglinide) or in addition to metformin 
(nateglinide and repaglinide) if other agents are not tolerated (Grade 2C). 
 
2 In patients with type 2 diabetes who are on meglitinides, consider the risk of 
hypoglycaemia and advise them about capillary blood glucose (CBG) monitoring 
accordingly (Grade 1D). 
 
3 Meglitinide dose reduction is advised in patients with CKD stages 4 and 5 who are on 
dialysis (Grade 2C). In these patients, due to hepatic metabolism, repaglinide is advised 
in preference to nateglinide (Grade 2C).   
Areas that require future research 
1 The clinical outcomes of meglitinides treatment in patients with type 2 diabetes and 
CKD. 
 
2 The efficacy and safety of meglitinides in patients with type 2 diabetes and all stages of 
CKD in attaining and retaining glucose control as mono, dual and triple therapy.  
 
3 The efficacy and safety of meglitinides with background insulin in patients with type 2 
diabetes and CKD. 
Audit standards 
1 The percentage of patients with type 2 diabetes and CKD who use meglitinides as 
mono or dual therapy, across the range of eGFRs. 
 
2 The percentage of patients with type 2 diabetes and CKD who are on meglitinides and 
are advised to monitor their CBG, across the range of eGFRs.   
 
3 The percentage of patients with an eGFR of <30 mL/min/1.73 m2 in whom the dose of 
meglitinides is reduced.  
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5 Metformin  
Recommendations 
1 Metformin can be used in patients who have diabetes, down to an estimated 
glomerular filtration rate (eGFR) of 30 mL/min/1.73 m2. The dosage should be reduced 
after the eGFR falls below 45 mL/min/1.73 m2 (Grade 1B). 
 
2 It should be recognised that, in certain circumstances, the eGFR may not give a true 
reflection of the actual GFR: for example in obese patients. In these circumstances, 
estimates of GFR using the cystatin C or Cockcroft–Gault formula may give a better 
estimate of GFR and enable metformin to be used even when the indirect eGFR might 
contraindicate its use (Grade 1C). 
 
3 Metformin should be withheld during periods of acute illness, particularly when a 
patient has acute kidney injury (AKI). All patients who are treated with metformin 
should be given sick day guidance (Appendix B) (Grade 1B). 
 
4 Metformin should be withheld prior to and shortly after any procedure that requires 
the use of radiographic contrast media (Grade 1B).  
Areas that require further research 
1 Does metformin reduce the risk of cardiovascular disease in patients with diabetes and 
chronic kidney disease (CKD)? 
2 Can metformin be used safely in patients who have more significant degrees of renal 
impairment (CKD stages 4–5) by monitoring circulating levels of metformin? 
3 What effect does the cessation of metformin have on glucose control and renal decline? 
4 How common is vitamin B12 deficiency in patients with CKD who are on metformin?  
Audit standards 
1 The proportion of patients with CKD on metformin who have received sick day guidance 
(Appendix B). 
2 The proportion of patients in whom metformin is stopped during acute illness, but in 
whom metformin is restarted on recovery.   
3 The proportion of patients with CKD who are on metformin and who have anaemia 
and/or neuropathy who have been tested for vitamin B12 deficiency.  
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6 Pioglitazone  
Recommendations 
1 We recommend that patients with type 2 diabetes and chronic kidney disease (CKD) of 
all stages can be considered for treatment with pioglitazone (Grade 1B). 
2 Pioglitazone should be avoided if there is evidence that a patient has heart failure or 
macular oedema (Grade 1B). 
3 Caution is required when commencing treatment in patients who have evidence of fluid 
overload. These patients should be monitored for fluid retention initially after 2 weeks, 
and 3–6-monthly thereafter (Grade 1C). 
4 We advise that patients with CKD who gain more than 20% of their body weight within 
the first 2 weeks should discontinue pioglitazone (Grade 2C). 
5 Caution is recommended when introducing pioglitazone in patients who have an 
increased risk of hip fractures (Grade 1C).  
6 Consider discontinuing pioglitazone in patients who develop hip fractures while they 
are on pioglitazone (Grade 1D). 
7 Do not start pioglitazone in patients who have known bladder cancer (Grade 1B). 
8 We suggest the discontinuation of pioglitazone in patients who have painless 
haematuria, until bladder cancer is excluded. This reflects the current National Institute 
for Health and Care Excellence (NICE) guidance on type 2 diabetes, pending any 
downgrading of NICE guidelines as suggested by the Association of British Clinical 
Diabetologists (ABCD) (Grades 2C–D). 
Areas that require future research 
1 The head-to-head comparison of pioglitazone with other oral hypoglycaemic agents, in 
terms of safety and efficiency, across the range of estimated glomerular filtration rates 
(eGFRs). 
2 The safety and efficiency of pioglitazone in combination with sodium glucose co-
transporter-2 (SGLT-2) receptor blockers. For example, the benefits of the volume-
reducing effect of SGLT-2 for pioglitazone-induced fluid retention; cardiovascular risk 
reduction; the effect on bone fractures; and the risks of urinary tract cancers with 
increased exposure to high glucose concentrations. 
3 The risk of bone fractures in patients who are on pioglitazone, in comparison with other 
therapies in patients who have type 2 diabetes and CKD. 
4 The efficacy and safety of pioglitazone as a third-line oral therapy in patients with type 2 
diabetes and CKD. 
5 The efficacy and safety of pioglitazone use with background insulin in patients with type 
2 diabetes. 
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6 The potential cardiovascular benefit of pioglitazone treatment in patients with type 2 
diabetes and chronic heart failure, where fluid retention is controlled by diuretics. 
7 The rate of renal function decline in patients with type 2 diabetes who are taking 
pioglitazone.  
Audit standards 
1 The proportion of patients with type 2 diabetes and CKD who are taking pioglitazone 
(with or without insulin) across the range of eGFRs.  
2 The proportion of patients with type 2 diabetes and CKD who are attaining and 
sustaining the recommended target HbA1C with pioglitazone as mono, dual or triple 
therapy, across the range of eGFRs. 
3 The rate of cardiovascular events in patients who are taking pioglitazone, across the 
range of eGFRs.  
4 The proportion of patients with type 2 diabetes and CKD who gain more than 20% of 
their body weight within the first 2 weeks of pioglitazone treatment, across the range of 
eGFRs. 
5 The rate of hip and other fractures among pioglitazone-treated patients who have type 2 
diabetes and CKD, across the range of eGFRs.  
6 The rate of heart failure that requires hospitalisation among pioglitazone-treated 
patients who have type 2 diabetes and CKD, across the range of eGFRs. 
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7 Dipeptidyl peptidase-4 inhibitors  
Recommendations 
1 We recommend that patients with type 2 diabetes and chronic kidney disease (CKD) of 
all stages be considered for treatment with dipeptidyl peptidase-4 (DPP-4) inhibitors 
(Grade 1B). 
2 We recommend that doses of all UK licensed DPP-4 inhibitors are appropriately reduced 
in accordance with the degree of renal impairment (including maintenance 
haemodialysis (MHDx)) except linagliptin (Grade 1B). 
3 Patients with type 2 diabetes and CKD can be safely prescribed DPP-4 inhibitors without 
the risk of hypoglycaemia or weight gain at all stages of renal disease (Grade 1B). 
4 There are no current data to recommend the use of DPP-4 inhibitors specifically to lower 
albuminuria in patients with type 2 diabetes and CKD (Grade 1C). 
5 There are no current data to suggest that DPP-4 inhibitors (except saxagliptin) are 
associated with an excess risk of hospitalisation for patients with heart failure, type 2 
diabetes and CKD (Grade 1A). 
Areas that require further research 
1 A head-to-head comparison of DPP-4 inhibitors with other oral hypoglycaemic agents 
(sulfonylureas and pioglitazone) that are licensed for use in patients with CKD, in terms 
of safety, efficacy, risk of hypoglycaemia, weight gain and hospitalisation for heart 
failure, across a wide range of eGFRs. 
2 The efficacy and safety of the use of a DPP-4 inhibitor with background insulin in 
patients with type 2 diabetes. 
3 A head-to-head comparison between various DPP-4 inhibitors with regard to HbA1c 
reduction in patients with type 2 diabetes and CKD. 
4 The mechanisms that underlie the potential differential effects of DPP-4 agents on 
albuminuria and their relationship with glucose lowering. 
Audit standards 
1 The proportion of patients with type 2 diabetes and CKD who are taking DPP-4 
inhibitors, according to the degree of renal impairment and across the ranges of 
estimated glomerular filtration rate (eGFR), including those who are on MHDx. 
2 The proportion of patients with type 2 diabetes and CKD who are taking appropriate 
doses of DPP-4 inhibitors, according to their degree of renal impairment. 
3 The proportion of patients with type 2 diabetes and CKD who are attaining the 
recommended target HbA1C with DPP-4 inhibitors as mono, dual and triple therapy, 
including insulin, according to their stage of CKD. 
4 The proportion of patients with type 2 diabetes and CKD who are sustaining the 
recommended target HbA1C with DPP-4 inhibitors as mono, dual and triple therapy, 
including insulin, according to their stage of CKD. 
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5 The proportion of patients with type 2 diabetes and CKD who are taking DPP-4 inhibitors 
who show a percentage reduction in albuminuria.  
6 The comparative efficacy of DPP-4 inhibitors in patients with type 2 diabetes and CKD, 
across the range of eGFRs.  
7 The incidence of hospitalisation of patients with heart failure who have type 2 diabetes 
and CKD and are being treated with DPP-4 inhibitors. 
8 The efficacy of glycaemic control (HbA1c reduction) with reduced doses of DPP-4 
inhibitors in patients with progressive renal impairment. 
Areas of concern 
1 The potential for heart failure in patients who have a high cardiovascular risk and CKD 
who are using DPP-4 inhibitors. 
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8 Sodium glucose co-transporter-2 inhibitors 
Recommendations 
1 Sodium glucose co-transporter-2 (SGLT-2) inhibitors are currently licensed for the 
treatment of type 2 diabetes only when the estimated glomerular filtration rate (eGFR) 
is >60 mL/min/1.73 m2. For dapagliflozin, the drug should be withheld when a patient’s 
eGFR falls below this level, while canagliflozin and empagliflozin may be continued until 
the eGFR falls below 45 mL/min/1.73 m2 (albeit at their lower licensed doses). We 
support these recommendations (Grade 1B). 
 
2 There is clinical trial evidence that empagliflozin and canagliflozin reduce cardiovascular 
outcomes in patients with type 2 diabetes who are at high cardiovascular risk (Grade 
1A). Subgroup analysis of these trials suggests that patients with an eGFR of 60 to <90 
mL/min/1.73 m2 gain cardiovascular benefit, so we recommend that this drug class be 
considered over other glucose-lowering therapies for patients with stage 2 chronic 
kidney disease (CKD) (Grade 2B). 
 
3 Pre-specified analyses of the same trials examined renal endpoints and showed the 
benefit of SGLT-2 inhibition for hard endpoints, such as changes in serum creatinine (and 
eGFR) and the need for end-stage renal replacement therapy. SGLT-2 inhibitors 
(currently empagliflozin and canagliflozin) are recommended for renoprotection for 
patients who have type 2 diabetes and are at high cardiovascular risk (Grade 1A). 
 
4 Patients with type 2 diabetes and CKD who are treated with SGLT-2 inhibitors need only 
perform frequent self-monitoring of blood glucose when they are also being treated 
with agents that can cause hypoglycaemia (such as sulfonylureas and insulins) (Grade 
1A). 
Areas that require future research 
1 The beneficial renal effects (seen as secondary endpoints) of empagliflozin and 
canagliflozin, observed down to an eGFR of 30 mL/min/1.73 m2 (ie CKD stage 3) need to 
be confirmed in studies with primary renal endpoints. This may ultimately lead to a 
change in the licence indication for SGLT-2 inhibitors. 
 
2 Research needs to establish whether the cardiovascular benefits of empagliflozin and 
canagliflozin also extend to patient with type 2 diabetes who have an eGFR of <30 
mL/min/1.73 m2, where the glycaemic effect of these agents is minimal. 
 
3 The beneficial cardiovascular effects of empagliflozin and canagliflozin need to be 
confirmed for other members of the SGLT-2 inhibitor class.  
 
4 Studies need to examine the cardiovascular and renal effects of SGLT-2 inhibitors in 
patients with type 2 diabetes who are at lower cardiovascular risk (who make up the 
majority of patients with type 2 diabetes) 
 
5 Trials need to investigate whether the renal and cardiovascular benefits of SGLT-2 
inhibitors are seen in patients with pre-diabetes and in the population who do not have 
diabetes. 
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6 The long-term impact of SGLT-2 inhibitors on metabolic bone disease, and parameters 
such as calcium, phosphate and magnesium should be investigated. 
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9 Glucagon-like peptide-1 receptor agonists 
Recommendations 
1 There is evidence that treatment with some glucagon-like peptide-1 receptor agonists 
(GLP-1RAs) reduces the progression of renal disease in patients with type 2 diabetes, but 
this mainly relates to the new onset of persistent macroalbuminuria (Grade 2B). To date, 
there has been no reported reduction in hard clinical endpoints, such as a doubling of 
serum creatinine or the need for continuous renal replacement therapy. Hence, the 
main aim of GLP-1RA therapy in patients with type 2 diabetes and chronic kidney disease 
(CKD) should be the improvement of glycaemic control with a low risk of both 
hypoglycaemia and weight gain (Grade 1A). 
 
2 There is emerging evidence of protection from cardiovascular disease with the use of 
some GLP-1RAs in patients who have type 2 diabetes and a high risk of cardiovascular 
disease (Grade 1A). In one sub-group analysis, this protection was more pronounced in 
patients with stage 3 CKD; GLP-1RAs may therefore be preferred over alternative 
glucose-lowering therapies (eg sulfonylureas and insulins) in this scenario (Grade 2C). 
 
3 There is no evidence that any of the GLP-1RAs lead to a progressive decline in renal 
filtration function; however, the licensed indications differ for drugs within the class. All 
GLP-1RAS can be prescribed for patients with CKD stages 1–2; however, we only 
recommend the use of agents that have a licensed indication for CKD stages 3 and 4 
(Grades 1A–1C). No GLP-1RAs are currently licensed for use in patients with CKD stage 5, 
or for patients who are on renal dialysis. 
 
4 Patients with type 2 diabetes and CKD who are treated with GLP-1RAs need to only 
perform regular self-monitoring of blood glucose when they are also being treated with 
agents that can cause hypoglycaemia (such as sulfonylureas and insulins). 
 
5 There is no role for the combination of GLP-1 analogues and dipeptidyl peptidase-4 
(DPP-4) inhibitors. 
Areas that require future research 
1 There is a need for studies on GLP-1RAs that have hard renal endpoints as their primary 
outcome (current studies have a primary outcome of composite cardiovascular disease 
events, with renal outcomes being classified as secondary microvascular events). 
 
2 Further studies of GLP-1RAs are needed in patients with CKD stage 5, including patients 
who are on renal dialysis (both haemodialysis and continuous peritoneal dialysis). 
 
3 There is a need to examine the risk of worsening diabetic retinopathy in patients with 
type 2 diabetes and CKD treated with GLP-1RAs, in light of the fact that two studies 
showed deterioration despite improving proteinuria endpoints. 
 
4 The use of a combination of GLP-1RAs and SGLT-2 inhibitors needs to be examined in 
patients with CKD, with a focus on renal endpoints.  
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5 The use of a combination of GLP-1RAs and insulin needs to be examined in patients with 
CKD, with a focus on renal endpoints. 
Audit standards  
1 The frequency of off-licence use of GLP-1RAs in patients with CKD stages 4 and 5. 
 
2 The combination of GLP-1RA and insulin use in patients with CKD. 
 
3 The combination of GLP-1RA and sodium glucose co-transporter-2 (SGLT-2) inhibitor use 
in patients with CKD. 
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